The chimeric antigen receptor (CAR) technology started out as a tool to understand lymphocyte
biology but rapidly developed into a T cell therapeutic agent for the treatment of cancers. Here, we
describe the technological advances in the field of CARs and highlight critical components of its success.
Additionally, we describe how various laboratories have worked toward developing new, safer,
and more potent CARs for cancer.